Touma, Zahi
Costenbader, Karen H.
Hoskin, Ben
Atkinson, Christian
Bell, David
Pike, James
Berry, Pamela
Karyekar, Chetan S.
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 7 June 2022
Accepted: 2 September 2023
First Online: 5 June 2024
Declarations
:
: Data collection was undertaken in line with European Pharmaceutical Marketing Research Association [] guidelines and as such it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [], and Health Information Technology for Economic and Clinical Health Act legislation. []. All patients gave written informed consent before any study-related procedures were performed.
: Not applicable.
: Zahi Touma collaborated with Janssen employees on this study, has acted as a consultant for AstraZeneca, Biogen IDEC, EMD Serono, Pfizer Inc., GlaxoSmithKline, Janssen Inc., UCB, Eli Lilly and Sarkana Pharma. Karen Costenbader collaborated with Janssen employees on this study, has acted as a consultant for AstraZeneca and Neutrolis, and has research collaborations with Glaxo Smith Kline, Lilly, Exagen Diagnostics, Gilead, Amgen and Merck. Ben Hoskin, Christian Atkinson, David Bell, and James Pike are employed by Adelphi Real World. Chetan Karyekar is an employee and shareholder of Janssen pharmaceuticals. Pamela Berry is an employee and shareholder of Janssen pharmaceuticals.